Literature DB >> 15653819

Preventing varicella-zoster disease.

Sophie Hambleton1, Anne A Gershon.   

Abstract

Varicella-zoster virus (VZV), the cause of chickenpox and shingles, is a pathogen in retreat following the introduction of mass vaccination in the United States in 1995. The live attenuated Oka vaccine, which is safe and immunogenic, gives good protection against both varicella and zoster in the short to medium term. It has undoubtedly been highly effective to date in reducing all forms of varicella, especially severe disease. However, the huge pool of latent wild-type virus in the population represents a continuing threat. Both the biology and the epidemiology of VZV disease suggest that new vaccination strategies will be required over time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653819      PMCID: PMC544176          DOI: 10.1128/CMR.18.1.70-80.2005

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  141 in total

1.  Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother.

Authors:  M B Salzman; R G Sharrar; S Steinberg; P LaRussa
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

3.  Visceral zoster as the presenting feature of disseminated herpes zoster.

Authors:  Erik Stratman
Journal:  J Am Acad Dermatol       Date:  2002-05       Impact factor: 11.527

Review 4.  Varicella: historical perspective and clinical overview.

Authors:  T H Weller
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

Review 5.  Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus.

Authors:  T H Weller
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

6.  Effectiveness over time of varicella vaccine.

Authors:  Marietta Vázquez; Philip S LaRussa; Anne A Gershon; Linda M Niccolai; Catherine E Muehlenbein; Sharon P Steinberg; Eugene D Shapiro
Journal:  JAMA       Date:  2004-02-18       Impact factor: 56.272

7.  Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged.

Authors:  R Berger; G Florent; M Just
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

Review 8.  Antiviral therapy in children with varicella zoster virus and herpes simplex virus infections.

Authors:  Andrea M Enright; Charles Prober
Journal:  Herpes       Date:  2003-08

9.  Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox.

Authors:  M Brisson; N J Gay; W J Edmunds; N J Andrews
Journal:  Vaccine       Date:  2002-06-07       Impact factor: 3.641

10.  Localization of varicella-zoster virus gene 21 protein in virus-infected cells in culture.

Authors:  R Mahalingam; R Lasher; M Wellish; R J Cohrs; D H Gilden
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more
  31 in total

1.  Monitoring prevalence of varicella-zoster virus clades in Germany.

Authors:  A Sauerbrei; J Stefanski; A Philipps; A Krumbholz; R Zell; P Wutzler
Journal:  Med Microbiol Immunol       Date:  2010-10-31       Impact factor: 3.402

2.  Case 2: Rash, fever and headache....first, do no harm.

Authors:  Jenny Wl Chou; Collin Yong; Susan H Wootton
Journal:  Paediatr Child Health       Date:  2008-01       Impact factor: 2.253

3.  Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality.

Authors:  Marc Brisson
Journal:  Can J Public Health       Date:  2008 Sep-Oct

Review 4.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

Review 5.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 6.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

7.  Early detection of Varicella-Zoster virus (VZV)-specific T-cells before seroconversion in primary varicella infection: case report.

Authors:  Armin Baiker; Rudolf Haase; Josef Eberle; Maria Guadalupe Vizoso Pinto; Klaus-Ingmar Pfrepper; Andreas Petrich; Ludwig Deml; Hartmut Campe; Hans Nitschko; Gundula Jaeger
Journal:  Virol J       Date:  2010-03-06       Impact factor: 4.099

8.  A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens.

Authors:  Maria G Vizoso Pinto; Klaus-Ingmar Pfrepper; Tobias Janke; Christina Noelting; Michaela Sander; Angelika Lueking; Juergen Haas; Hans Nitschko; Gundula Jaeger; Armin Baiker
Journal:  Virol J       Date:  2010-07-20       Impact factor: 4.099

9.  The epidemiology of Varicella Zoster Virus infection in Italy.

Authors:  Giovanni Gabutti; Maria C Rota; Marcello Guido; Antonella De Donno; Antonino Bella; Marta L Ciofi degli Atti; Pietro Crovari
Journal:  BMC Public Health       Date:  2008-10-27       Impact factor: 3.295

Review 10.  Herpes zoster associated hospital admissions in Italy: review of the hospital discharge forms.

Authors:  Giovanni Gabutti; Carlotta Serenelli; Alessandra Cavallaro; Pietro Ragni
Journal:  Int J Environ Res Public Health       Date:  2009-09-02       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.